Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Position Increased by Janus Henderson Group PLC

Janus Henderson Group PLC boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 31.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 221,063 shares of the company's stock after acquiring an additional 52,563 shares during the quarter. Janus Henderson Group PLC owned 0.39% of Harmony Biosciences worth $7,607,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. KBC Group NV increased its position in shares of Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after acquiring an additional 819 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after purchasing an additional 519 shares during the period. Summit Investment Advisors Inc. increased its holdings in Harmony Biosciences by 34.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company's stock valued at $137,000 after purchasing an additional 1,029 shares in the last quarter. Avanza Fonder AB purchased a new position in Harmony Biosciences in the fourth quarter valued at about $145,000. Finally, CIBC Private Wealth Group LLC lifted its stake in shares of Harmony Biosciences by 66.4% during the fourth quarter. CIBC Private Wealth Group LLC now owns 4,214 shares of the company's stock worth $146,000 after purchasing an additional 1,681 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Cantor Fitzgerald raised Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Needham & Company LLC reissued a "buy" rating and set a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They set a "buy" rating and a $55.00 price target on the stock. Finally, UBS Group lowered their target price on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Monday, April 28th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Harmony Biosciences currently has an average rating of "Buy" and a consensus target price of $52.78.

Harmony Biosciences Stock Performance

HRMY traded up $0.04 during trading hours on Friday, hitting $34.17. 392,819 shares of the stock were exchanged, compared to its average volume of 600,606. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a 12 month low of $26.47 and a 12 month high of $41.61. The stock has a 50-day simple moving average of $31.58 and a 200-day simple moving average of $34.02. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 16.19, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $184.73 million for the quarter, compared to analyst estimates of $184.26 million. During the same quarter in the prior year, the business earned $0.67 earnings per share. Harmony Biosciences's quarterly revenue was up 19.5% on a year-over-year basis. Analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.